Kidney Function Tests: Understanding eGFR and BUN

This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before making health decisions based on this content.

By MeridianMedicalCentre.com Health Research Team | Last verified: August 2026

What Kidney Function Tests Are: Classification and Clinical Purpose

Kidney function tests are laboratory measurements that assess how well your kidneys filter waste products from your blood. The two primary markers are:

eGFR (Estimated Glomerular Filtration Rate)

eGFR estimates the volume of blood your kidneys filter each minute, measured in millilitres per minute per 1.73 m² of body surface area (mL/min/1.73m²). It is not directly measured but calculated from serum creatinine (a waste product from muscle metabolism), age, sex, race, and body composition using validated equations. eGFR is the primary screening tool for chronic kidney disease worldwide.

BUN (Blood Urea Nitrogen)

BUN measures nitrogen in the form of urea, another waste product filtered by the kidneys. While less specific than eGFR, BUN provides context about hydration status and protein metabolism. It appears alongside creatinine in routine metabolic panels and is used to calculate the BUN-to-creatinine ratio, which helps differentiate types of kidney injury.

Normal Reference Ranges

eGFR: 90 mL/min/1.73m² or higher is considered normal kidney function; values below 60 warrant further evaluation.

BUN: 7–20 mg/dL (2.5–7.1 mmol/L) is typical for adults; values above 23 mg/dL may indicate kidney stress, dehydration, or high protein diet.

How Kidney Function Tests Work: The Biological Mechanism

The Glomerular Filtration Process

The kidneys contain approximately 1 million functional units called nephrons. Each nephron begins with a glomerulus—a network of tiny blood vessels that acts as a filter. Blood pressure forces water and small waste molecules (creatinine, urea, excess ions) across the glomerular membrane into the tubule. Larger proteins and blood cells remain in the blood. The filtrate continues through the tubule, where useful substances (glucose, amino acids, water) are reabsorbed; remaining waste becomes urine.

Why eGFR Reflects Kidney Function

Creatinine is produced at a relatively constant rate proportional to muscle mass. Healthy kidneys filter nearly all creatinine into urine. When kidney function declines, less creatinine is filtered, so serum creatinine rises. eGFR mathematically converts this creatinine elevation into a filtration rate, allowing clinicians to stage disease severity and monitor progression. Unlike BUN, creatinine is not significantly affected by diet or hydration in stable conditions.

BUN as a Secondary Marker

Urea is produced from protein breakdown and is freely filtered by healthy kidneys. However, urea is reabsorbed in the tubule, so BUN reflects both kidney function and protein intake, hydration status, and liver function. A high BUN-to-creatinine ratio (above 20:1) suggests dehydration or prerenal causes of kidney stress; a ratio below 10:1 may indicate liver disease or low protein diet. This context makes BUN particularly useful in acute settings.

What the Research Shows: Clinical Evidence and Interpretation

eGFR Staging and CKD Prevalence

The National Kidney Foundation (Grade A evidence) defines chronic kidney disease in five stages based on eGFR:

• Stage 1: eGFR ≥90 (normal, but kidney damage present—proteinuria, imaging findings)
• Stage 2: eGFR 60–89 (mild reduction, function usually adequate)
• Stage 3a: eGFR 45–59 (moderate reduction; increased monitoring needed)
• Stage 3b: eGFR 30–44 (moderate-severe reduction; medication review required)
• Stage 4: eGFR 15–29 (severe reduction; prepare for replacement therapy)
• Stage 5: eGFR <15 (kidney failure; dialysis or transplant required)

Approximately 10–15% of U.S. adults have CKD based on eGFR or albuminuria, yet many are unaware (Grade A, NHANES data).

Prognostic Value and Early Detection

Landmark cohort studies (MDRD, CKD-EPI) demonstrate that eGFR independently predicts progression to kidney failure, cardiovascular events, and mortality. A single low eGFR requires confirmation; two abnormal results three months apart confirm CKD. Early detection allows intervention with ACE inhibitors, ARBs, and SGLT2 inhibitors, which slow disease progression by 20–50% (Grade A evidence from RCTs).

Limitations of Current Tests

eGFR has known limitations: it underestimates true GFR in older adults with low muscle mass and overestimates in very muscular individuals. Race-based adjustments historically used in eGFR equations (Chronic Kidney Disease Epidemiology Collaboration) have been removed in 2021 updates to reduce disparities. BUN is nonspecific and varies with protein diet, hydration, and catabolic state, making it unsuitable as a sole indicator of kidney function.

Forms and Measurement Methods: How Tests Are Performed

eGFR Calculation Methods

eGFR is calculated using validated equations based on serum creatinine. Common equations include:

• CKD-EPI 2021: Recommended globally; incorporates creatinine, age, sex, and body surface area without race adjustment
• MDRD: Older equation; still used in some labs
• Cystatin C–based: Alternative marker less dependent on muscle mass; used when creatinine unreliable

Your lab report automatically calculates eGFR; no additional steps required.

Sample Collection and Timing

Both tests require a single fasting or non-fasting blood sample. Results are typically available within 24–48 hours. Baseline testing is recommended for all adults over 65, those with diabetes, hypertension, or family history of kidney disease, and anyone taking nephrotoxic medications (NSAIDs, ACE inhibitors, aminoglycosides).

Who Should Consider Testing and Who Requires Special Attention

Screening Recommendations

All adults should have baseline kidney function testing. Repeat testing frequency depends on results and risk factors:

• Normal eGFR, no albuminuria: Retest every 1–2 years if at risk; 5 years if low risk
• Stage 2–3a CKD: Annual testing
• Stage 3b–4 CKD: Every 3–6 months
• Stage 5 CKD: Monthly or as clinically indicated

High-Risk Populations

• Diabetes (Type 1 or 2): Annual eGFR and albuminuria testing (Grade A)
• Hypertension: Annual testing; more frequent if on ACE inhibitor or ARB
• Autoimmune disease (lupus, vasculitis): Regular monitoring; every 3–6 months
• Family history of kidney disease: Baseline and periodic screening
• Older adults (≥65 years): Baseline and annual testing
• Acute illness, sepsis, or major surgery: Acute kidney injury risk; frequent repeat testing

Special Considerations

Pregnancy: Glomerular filtration increases by 30–50% during pregnancy; “normal” eGFR values are higher. Pregnancy-specific reference ranges should be used.

Obesity and extremes of body composition: eGFR may be inaccurate; cystatin C or measured GFR may be requested.

Acute kidney injury: eGFR lags behind true GFR decline; rising creatinine and falling urine output are primary indicators.

Safety and Clinical Considerations

Testing Safety

Kidney function tests are non-invasive blood draws; risks are minimal (minor bruising at venipuncture site). No contraindications to testing exist.

Clinical Action Based on Results

Abnormal results require clinical correlation. A single abnormal result does not diagnose CKD. Actions depend on the clinical context:

• Mild eGFR reduction (60–89): Confirm in 3 months; check for albuminuria; review medications
• Moderate reduction (30–59): Initiate nephrology referral; adjust medication doses; monitor mineral metabolism
• Severe reduction (<30): Urgent nephrology referral; begin planning for renal replacement therapy
• Elevated BUN with normal creatinine: Assess hydration, protein intake, and hemoglobin

Medication Adjustment

Many drugs require dose adjustment based on eGFR: antibiotics (aminoglycosides, fluoroquinolones), antivirals, and cardiovascular drugs. Always inform prescribers of kidney function test results.